MedTrace Logo

Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer

NCT05709249 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 730

Last updated 2024-12-30

No results posted yet for this study

Summary

This study is designed as a multi-center, randomized, double-blind, placebo-controlled trial. Subjects in the intervention group will be treated with XLJDOD compound granule. Subjects in the control group will be treated with placebo (XLJDOD mimetic agent).

Conditions

Interventions

DRUG

XLJDOD compound granule

Treatment will begin within 3 months after standard adjuvant chemotherapy and compliance will be continuously monitored. XLJDOD will be taken twice a day, infused with warm water, 1 hour after lunch and dinner. One course of treatment will take 28 days in 1 month, and 2- to 3-day rest. Treatment will continue for 6 courses.

DRUG

placebo (XLJDOD mimetic agent)

The course of placebo in control group will be in accordance with that of XLJDOD in intervention group.

Sponsors & Collaborators

  • Jiangsu Province Hospital of Traditional Chinese Medicine

    collaborator OTHER

  • Ministry of Science and Technology of the People´s Republic of China

    collaborator OTHER_GOV

  • Jiangsu Famous Medical Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2027-04-01
Completion
2028-04-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05709249 on ClinicalTrials.gov